CN100484536C - Capsule for treating enteritis and dysentery and its preparing process - Google Patents
Capsule for treating enteritis and dysentery and its preparing process Download PDFInfo
- Publication number
- CN100484536C CN100484536C CNB2006100185982A CN200610018598A CN100484536C CN 100484536 C CN100484536 C CN 100484536C CN B2006100185982 A CNB2006100185982 A CN B2006100185982A CN 200610018598 A CN200610018598 A CN 200610018598A CN 100484536 C CN100484536 C CN 100484536C
- Authority
- CN
- China
- Prior art keywords
- capsule
- dysentery
- dandelion
- ethanol
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 39
- 208000001848 dysentery Diseases 0.000 title claims abstract description 14
- 208000004232 Enteritis Diseases 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 22
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 19
- 229920002472 Starch Polymers 0.000 claims abstract description 11
- 239000008107 starch Substances 0.000 claims abstract description 11
- 235000019698 starch Nutrition 0.000 claims abstract description 11
- 239000008187 granular material Substances 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 241000245665 Taraxacum Species 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000012567 medical material Substances 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 229940067866 dandelion extract Drugs 0.000 abstract description 21
- 235000020691 dandelion extract Nutrition 0.000 abstract description 21
- 239000001845 taraxacum officinale leaf extract Substances 0.000 abstract description 21
- 239000000463 material Substances 0.000 abstract description 18
- 239000000203 mixture Substances 0.000 abstract description 10
- 235000019658 bitter taste Nutrition 0.000 abstract description 3
- 239000003086 colorant Substances 0.000 abstract description 2
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 29
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 14
- 238000000605 extraction Methods 0.000 description 9
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 7
- 229940074360 caffeic acid Drugs 0.000 description 7
- 235000004883 caffeic acid Nutrition 0.000 description 7
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000011835 investigation Methods 0.000 description 6
- 208000004396 mastitis Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 201000001352 cholecystitis Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000003359 percent control normalization Methods 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000292546 Taraxacum mongolicum Species 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000035603 choleresis Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- -1 filter Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000011224 negative regulation of urine volume Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
一种治疗肠炎痢疾的胶囊及其制备工艺,它包含有处方量的主药盐酸小檗碱、蒲公英浸膏和辅料淀粉组成。该片剂特点是可掩盖药的苦味,可具有各种颜色还可印字,且美观,利于服用,携带和使用方便,药物的生物利用度高,提高药物稳定性。制备工艺采用取盐酸小檗碱、蒲公英浸膏二药加淀粉52.5g充分混匀,用75%乙醇制成颗粒,干燥,灌装成1000粒胶囊,即得。A capsule for treating enteritis and dysentery and its preparation process, which comprises a prescription amount of the main drug berberine hydrochloride, dandelion extract and auxiliary material starch. The feature of the tablet is that it can cover the bitter taste of the medicine, can have various colors and can be printed, and is beautiful, easy to take, easy to carry and use, has high bioavailability of the medicine, and improves the stability of the medicine. The preparation process is to take berberine hydrochloride and dandelion extract, add 52.5g of starch and mix thoroughly, make granules with 75% ethanol, dry, and fill into 1000 capsules.
Description
技术领域 technical field
本发明涉及一种治疗肠炎痢疾的胶囊及其制备工艺。The invention relates to a capsule for treating enteritis and dysentery and a preparation process thereof.
背景技术 Background technique
以盐酸小檗碱和蒲公英浸膏为主要原料制成的连蒲双清片对治疗肠炎痢疾,疖肿外伤发炎,乳腺炎,胆囊炎有比较好的疗效。再次开发中成药连蒲双清胶囊由其重要,因为改成胶囊,有很多优点:可掩盖药的苦味,可具有各种颜色还可印字,且美观,利于服用,携带和使用方便,药物的生物利用度高,提高药物稳定性。Lianpu Shuangqing Tablet, which is made of berberine hydrochloride and dandelion extract as the main raw materials, has a relatively good curative effect on the treatment of enteritis and dysentery, boils, traumatic inflammation, mastitis, and cholecystitis. It is very important to re-develop the Chinese patent medicine Lianpu Shuangqing Capsule, because changing it into a capsule has many advantages: it can mask the bitter taste of the medicine, it can have various colors and can be printed, and it is beautiful, easy to take, easy to carry and use, and the bioavailability of the medicine High degree, improve drug stability.
目前国内有针对性治疗肠炎痢疾,疖肿外伤发炎,乳腺炎,胆囊炎等症中成药相对比较多。而在国内外治疗肠炎痢疾,疖肿外伤发炎,乳腺炎,胆囊炎等症的西药对人体的副作用相当大,甚至危及生命,不可多用。本发明的清热解毒,燥湿止痢中成药片剂是以传统中医理论指导下运用现代制剂技术精制而成。At present, there are relatively many Chinese patent medicines in China for the targeted treatment of enteritis and dysentery, boils, traumatic inflammation, mastitis, and cholecystitis. And treat enteritis dysentery at home and abroad, furuncle swollen wound inflammation, mastitis, the western medicine of diseases such as cholecystitis are sizable to the side effect of human body, even life-threatening, can not be used more often. The heat-clearing and toxic-drying, damp-dampness-relieving and dysentery Chinese patent medicine tablet of the present invention is refined by using modern preparation technology under the guidance of traditional Chinese medicine theories.
发明内容 Contents of the invention
本发明的目的是提供一种治疗肠炎痢疾的胶囊。The object of the invention is to provide a capsule for treating enteritis and dysentery.
本发明的另一目的是提供一种治疗肠炎痢疾的胶囊制备方法。Another object of the present invention is to provide a capsule preparation method for treating enteritis and dysentery.
本发明是这样来实现的,它包括主药和辅料,其中主药由下列重量份原料药配制而成:盐酸小檗碱7-13蒲公英浸膏127.5-247.5The present invention is realized in this way, it comprises main medicine and auxiliary material, and wherein main medicine is prepared by following raw material medicine by weight: berberine hydrochloride 7-13 dandelion extract 127.5-247.5
其中辅料为淀粉52.5g、浓度为60-80%的乙醇。Wherein the auxiliary materials are 52.5 g of starch and ethanol with a concentration of 60-80%.
本发明的制备方法:取盐酸小檗碱、蒲公英浸膏二药加淀粉52.5g充分混匀,用75%乙醇制成颗粒,干燥,灌装成1000粒胶囊,即得。The preparation method of the present invention: take berberine hydrochloride and dandelion extract, add 52.5 g of starch and mix thoroughly, make granules with 75% ethanol, dry, fill into 1000 capsules, and get final product.
蒲公英浸膏制法:取蒲公英药材打成细粉,过100目筛,备用;另取蒲公英药材加12倍量水煎煮2次,第一次1.5小时,第二次1小时,合并煎煮液,滤过,滤液浓缩至相对密度1.20清膏在温度70~75℃热测的,取清膏1.2份,蒲公英细粉1份,混匀,干燥,制成干膏,即得。Preparation method of dandelion extract: Take dandelion medicinal material, grind it into fine powder, pass through a 100-mesh sieve, and set aside; take another dandelion medicinal material and add 12 times the amount of water to decoct twice, the first time is 1.5 hours, the second time is 1 hour, combined decoction liquid, filtered, and the filtrate was concentrated to a relative density of 1.20. The clear paste was measured at a temperature of 70-75°C. Take 1.2 parts of the clear paste and 1 part of dandelion fine powder, mix well, and dry to make a dry paste.
本发明的优点是:药物的生物利用高,药物稳定性好,利于服用,携带方便,可掩盖药的苦味。The invention has the advantages of high bioavailability of the medicine, good stability of the medicine, convenient taking, convenient carrying, and can cover the bitter taste of the medicine.
具体实施方式 Detailed ways
实施例一、Embodiment one,
盐酸小檗碱 10g 蒲公英浸膏 187.5gBerberine Hydrochloride 10g Dandelion Extract 187.5g
本发明的制备方法:取盐酸小檗碱、蒲公英浸膏二药加淀粉52.5g充分混匀,用75%乙醇制成颗粒,干燥,灌装成1000粒胶囊,即得。The preparation method of the present invention: take berberine hydrochloride and dandelion extract, add 52.5 g of starch and mix thoroughly, make granules with 75% ethanol, dry, fill into 1000 capsules, and get final product.
蒲公英浸膏制法:取蒲公英药材打成细粉,过100目筛,备用;另取蒲公英药材加12倍量水煎煮2次,第一次1.5小时,第二次1小时,合并煎煮液,滤过,滤液浓缩至相对密度1.20的清膏,在温度70~75℃测的,取清膏1.2份,蒲公英细粉1份,混匀,干燥,制成干膏,即得。Preparation method of dandelion extract: Take dandelion medicinal material, grind it into fine powder, pass through a 100-mesh sieve, and set aside; take another dandelion medicinal material and add 12 times the amount of water to decoct twice, the first time is 1.5 hours, the second time is 1 hour, combined decoction Liquid, filtered, the filtrate concentrated to a clear paste with a relative density of 1.20, measured at a temperature of 70-75°C, take 1.2 parts of the clear paste, 1 part of dandelion fine powder, mix well, dry, and make a dry paste.
实施例二、Embodiment two,
盐酸小檗碱 7g 蒲公英浸膏 127.5gBerberine Hydrochloride 7g Dandelion Extract 127.5g
本发明的制备方法:取盐酸小檗碱、蒲公英浸膏二药加淀粉52.5g充分混匀,用65%乙醇制成颗粒,干燥,灌装成1000粒胶囊,即得。The preparation method of the present invention: take berberine hydrochloride and dandelion extract, add 52.5 g of starch and mix thoroughly, make granules with 65% ethanol, dry, fill into 1000 capsules, and get final product.
蒲公英浸膏制法:取蒲公英药材打成细粉,过100目筛,备用;另取蒲公英药材加12倍量水煎煮2次,第一次1.5小时,第二次1小时,合并煎煮液,滤过,滤液浓缩至相对密度1.20的清膏,在温度70~75℃测的,取清膏1.2份,蒲公英细粉1份,混匀,干燥,制成干膏,即得。Preparation method of dandelion extract: Take dandelion medicinal material, grind it into fine powder, pass through a 100-mesh sieve, and set aside; take another dandelion medicinal material and add 12 times the amount of water to decoct twice, the first time is 1.5 hours, the second time is 1 hour, combined decoction Liquid, filtered, the filtrate concentrated to a clear paste with a relative density of 1.20, measured at a temperature of 70-75°C, take 1.2 parts of the clear paste, 1 part of dandelion fine powder, mix well, dry, and make a dry paste.
实施例三、Embodiment three,
盐酸小檗碱 13g 蒲公英浸膏 247.5gBerberine Hydrochloride 13g Dandelion Extract 247.5g
本发明的制备方法:取盐酸小檗碱、蒲公英浸膏二药加淀粉52.5g充分混匀,用85%乙醇制成颗粒,干燥,灌装成1000粒胶囊,即得。The preparation method of the present invention: take berberine hydrochloride and dandelion extract, add 52.5 g of starch and mix thoroughly, make granules with 85% ethanol, dry, fill into 1000 capsules, and obtain.
研究结果:Research result:
一、制备工艺研究资料1. Preparation process research data
1与工艺选择有关的药效及成分的论述1 Discussion on the efficacy and ingredients related to process selection
本方由盐酸小檗碱、蒲公英浸膏组成。This prescription is composed of berberine hydrochloride and dandelion extract.
1.1、盐酸小檗碱为原料药,有较强的抗微生物及抗原虫作用;盐酸小檗碱具有降压、松弛血管平滑肌、利胆、抗利尿、局部麻醉、镇静、镇痛等作用。因此,为了最大限度保留其有效成分,盐酸小檗碱采用直接加入工艺更为合理。1.1. Berberine hydrochloride is the raw material drug, which has strong antimicrobial and antiprotozoal effects; berberine hydrochloride has the effects of lowering blood pressure, relaxing vascular smooth muscle, promoting choleresis, antidiuresis, local anesthesia, sedation, and analgesia. Therefore, in order to retain its active ingredients to the greatest extent, it is more reasonable to adopt the direct addition process of berberine hydrochloride.
1.2、蒲公英全草含蒲公英甾醇、胆碱、菊糖和果胶等脂溶性和水溶性成分。蒲公英是清热解毒的传统药物,近年来通过进一步研究,证明它有良好的抗感染作用,广泛应用于临床各科多种感染性炎症。因此,该处方采用部分药材打粉、部分药材煎煮工艺既最大限度保留其有效成分又减少服用量。1.2. Dandelion whole herb contains fat-soluble and water-soluble components such as dandelion sterol, choline, inulin and pectin. Dandelion is a traditional medicine for clearing heat and detoxifying. In recent years, through further research, it has been proved that it has good anti-infection effect, and it is widely used in various clinical departments for various infectious inflammations. Therefore, the prescription adopts the process of powdering some medicinal materials and decocting some medicinal materials, which not only retains its active ingredients to the greatest extent, but also reduces the dosage.
2 提取工艺条件考察2 Investigation of extraction process conditions
该处方由盐酸小檗碱及蒲公英浸膏组成,因此,工艺主要考察蒲公英浸膏制备条件。蒲公英浸膏采用水煎煮提取方法,影响水提工艺的因素主要有煎煮次数、煎煮时间及加水量。试验以干浸膏得率及蒲公英浸膏中咖啡酸含量为考察指标进行水提工艺的研究确定。The prescription is composed of berberine hydrochloride and dandelion extract. Therefore, the process mainly examines the preparation conditions of dandelion extract. The dandelion extract is extracted by decoction, and the main factors affecting the water extraction process are decoction times, decoction time and water addition. In the experiment, the yield of dry extract and the content of caffeic acid in dandelion extract were used as the investigation indicators to study and determine the water extraction process.
试验材料:蒲公英原药材购自樟树市医药公司,产于江西吉安。经我公司按《中国药典》2000年一部蒲公英药材标准鉴定及检测,投料药材为菊科植物蒲公英Taraxacum mongolicum Hand.-Mazz.的干燥全草,测定蒲公英中咖啡酸含量为0.029%。Experimental materials: The original medicinal materials of dandelion were purchased from Zhangshu Pharmaceutical Company and produced in Ji'an, Jiangxi. According to the identification and testing of a dandelion medicinal material standard in "Chinese Pharmacopoeia" in 2000, the raw material is the dried whole herb of Compositae plant dandelion Taraxacum mongolicum Hand.-Mazz. The caffeic acid content in dandelion is determined to be 0.029%.
咖啡酸含量测定方法:按《中国药典》2000年一部蒲公英药材标准含量测定项下咖啡酸含量测定方法。Determination method of caffeic acid content: according to the determination method of caffeic acid content under the standard content determination item of a dandelion medicinal material in "Chinese Pharmacopoeia" in 2000.
2.1 蒲公英水煎煮提取次数的确定:参照原工艺,在煎煮时间均为2小时、加水量为12倍(根据蒲公英为全草药材,所占体积大而确定)时,试验考察水煎煮次数结果(见表1)2.1 Determination of the times of decoction and extraction of dandelion: referring to the original process, when the decoction time is 2 hours and the amount of water added is 12 times (determined based on the fact that dandelion is a whole herbal medicinal material and occupies a large volume), the decoction Number of results (see Table 1)
表1 蒲公英水煎煮提取次数考察Table 1 Investigation on the times of decoction and extraction of dandelion
由上表结果可以看出:蒲公英在加12倍量水煎煮两次,能充分提取其有效成分咖啡酸,因此确定此工艺煎煮提取次数为2次。From the results in the above table, it can be seen that the active ingredient caffeic acid can be fully extracted by decocting dandelion twice with 12 times the amount of water, so it is determined that the decoction extraction times of this process is 2 times.
2.2 蒲公英水煎煮提取煎煮时间的确定:参照原工艺,在提取次数为2次、加水量为12倍的条件下,试验考察水煎煮时间结果(见表2)2.2 Determination of decoction time for dandelion decoction extraction: refer to the original process, under the conditions of 2 times of extraction and 12 times the amount of water added, test the results of decoction time (see Table 2)
表2 蒲公英水煎煮提取煎煮时间考察Table 2 Investigation on the decoction time of dandelion decoction and extraction
由上表结果可以看出:蒲公英在加水12倍量煎煮,第一次1.5小时、第二次1小时即能使咖啡酸充分提取出来,因此确定此工艺煎煮时间为第一次1.5小时,第二次1小时是最佳煎煮工艺。From the results in the table above, it can be seen that when dandelion is decocted with 12 times the amount of water, the caffeic acid can be fully extracted in 1.5 hours for the first time and 1 hour for the second time, so the decoction time of this process is determined to be 1.5 hours for the first time , the second 1 hour is the best decoction process.
2.3 蒲公英水煎煮提取加水量的确定:参照原工艺,在提取次数为2次、第一次1.5小时,第二次1小时的条件下,试验考察水煎煮加水量结果(见表3)2.3 Determination of the amount of water added for decoction of dandelion: refer to the original process, under the condition that the number of extractions is 2 times, the first time is 1.5 hours, and the second time is 1 hour, the results of water decoction are tested (see Table 3)
表3 蒲公英水煎煮提取加水量考察Table 3 Investigation on the amount of water added for decoction and extraction of dandelion
由上表结果可以看出:蒲公英在加水12倍量煎煮,第一次1.5小时、第二次1小时即能使咖啡酸充分提取出来,因此确定此工艺煎煮加水量为12倍为最佳煎煮工艺。From the results in the table above, it can be seen that when dandelion is decocted with 12 times the amount of water, the caffeic acid can be fully extracted in 1.5 hours for the first time and 1 hour for the second time. Best decoction process.
3 辅料用量的确定3 Determination of the amount of excipients
根据处方投料总量为197.5g,制成1000粒胶囊计算,试验以每粒胶囊内容物装0.20g/粒、0.25g/粒、0.30g/粒考察,结果内容物装0.25g/粒及0.30g/粒的胶囊,其含量测定稳定性较好,为了减少服用量及降低生产成本,确定内容物装0.25g/粒的胶囊,故每1000粒胶囊需加淀粉52.5g。According to the total amount of prescription feeding is 197.5g, 1000 capsules are made, and the test is carried out by loading 0.20g/capsule, 0.25g/capsule, and 0.30g/capsule in each capsule, and the result is 0.25g/capsule and 0.30g/capsule. The capsules with g/capsules have good content determination stability. In order to reduce the dosage and production cost, it is determined that the contents are filled with 0.25g/capsules, so 52.5g of starch should be added for every 1000 capsules.
4 不同浓度乙醇对颗粒成型影响4 Effect of different concentrations of ethanol on particle formation
不同浓度的乙醇是制粒的关键因素,实验以65%、75%、85%三种乙醇浓度进行制粒考察,结果如下:Different concentrations of ethanol are the key factors for granulation. The experiments were carried out with three ethanol concentrations of 65%, 75%, and 85%. The results are as follows:
表4 不同浓度乙醇对颗粒制备的考察Table 4 The investigation of different concentrations of ethanol on the preparation of particles
由上表试验结果,我公司确定用75%乙醇制粒为最佳制粒工艺。According to the test results in the above table, our company determines that granulation with 75% ethanol is the best granulation process.
4.5 胶囊型号的确定4.5 Determination of capsule type
试验以0号胶囊试装,内容物每粒装0.25g,装量差异均符合规定,故确定胶囊型号为0号。In the test, No. 0 capsules were used for trial loading, and the content was 0.25g per capsule. The difference in the filling volume was in compliance with the regulations, so the capsule model was determined to be No. 0.
4.6 制备工艺的确定4.6 Determination of preparation process
通过以上工艺优选试验,确定连蒲双清胶囊的制备工艺为:Through the process optimization test above, it is determined that the preparation process of Lianpu Shuangqing Capsules is:
取盐酸小檗碱10g、蒲公英浸膏187.5g二药加淀粉52.5g混匀,用75%乙醇制粒,干燥,灌装成1000粒胶囊,即得。Take 10 g of berberine hydrochloride, 187.5 g of dandelion extract and 52.5 g of starch, mix them evenly, granulate with 75% ethanol, dry, fill into 1000 capsules, and get final product.
注蒲公英浸膏制法:取蒲公英药材打成细粉,过100目筛,备用;另取蒲公英药材加12倍量水煎煮2次,第一次1.5小时,第二次1小时,合并煎煮液,滤过,滤液浓缩至相对密度1.20(70~75℃热测)的清膏,取清膏1.2份,蒲公英细粉1份,混匀,干燥,制成干膏,即得。Note the preparation method of dandelion extract: Take dandelion medicinal materials, grind them into fine powder, pass through a 100-mesh sieve, and set aside; take another dandelion medicinal materials and add 12 times the amount of water to decoct twice, the first time is 1.5 hours, the second time is 1 hour, and combined decoction Boil the liquid, filter, and concentrate the filtrate to a clear paste with a relative density of 1.20 (70-75°C thermal measurement), take 1.2 parts of the clear paste, 1 part of dandelion fine powder, mix well, dry, and make a dry paste.
二、质量稳定性试验2. Quality stability test
取本品按市售包装放置于40℃,相对湿度为75%的恒温恒湿箱内6个月,经0、1、2、3、6月取样,进行考察项目为性状、鉴别、崩解时限、含量测定、微生物限度检查。各项指标均无明显变化,较稳定,有效期可达到三年。结果见表5。Take this product according to the commercially available package and place it in a constant temperature and humidity box at 40°C and a relative humidity of 75% for 6 months. After sampling in 0, 1, 2, 3, and 6 months, the inspection items are traits, identification, and disintegration. Time limit, content determination, microbial limit check. There is no significant change in all indicators, relatively stable, and the validity period can reach three years. The results are shown in Table 5.
表5 本发明胶囊稳定性加速试验(批号:20040418)Table 5 Accelerated test of capsule stability of the present invention (batch number: 20040418)
三、连蒲双清胶囊的临床应用效果:3. The clinical application effect of Lianpu Shuangqing capsule:
1、用连蒲双清胶囊作观察组(100例),以连蒲双清片为对照组(50例),在治疗肠炎痢疾进行临床比较,观察大便次数、大便性状、病程腹泻程度、腹痛、肠粘膜损伤程度,其疗效比较如下:1. Use Lianpu Shuangqing Capsules as the observation group (100 cases) and Lianpu Shuangqing Tablets as the control group (50 cases) to conduct clinical comparisons in the treatment of enteritis and dysentery, and observe the frequency of stool, stool properties, course of disease, degree of diarrhea, abdominal pain, and intestinal mucosal damage The degree of efficacy is compared as follows:
表6 连蒲双清胶囊治疗肠炎痢疾临床疗效比较Table 6 Comparison of clinical efficacy of Lianpu Shuangqing Capsules in the treatment of enteritis and dysentery
2、用连蒲双清胶囊作观察组(80例),以连蒲双清片为对照组(40例),在治疗乳腺炎进行临床比较,观察分析乳腺病程情况,其疗效比较如下:2. Using Lianpu Shuangqing Capsules as the observation group (80 cases), and Lianpu Shuangqing Tablets as the control group (40 cases), clinical comparison was carried out in the treatment of mastitis, and the course of mammary gland disease was observed and analyzed. The curative effects were compared as follows:
表7 连蒲双清胶囊治疗乳腺炎临床疗效比较Table 7 Comparison of clinical efficacy of Lianpu Shuangqing Capsules in the treatment of mastitis
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100185982A CN100484536C (en) | 2006-03-16 | 2006-03-16 | Capsule for treating enteritis and dysentery and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100185982A CN100484536C (en) | 2006-03-16 | 2006-03-16 | Capsule for treating enteritis and dysentery and its preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1857360A CN1857360A (en) | 2006-11-08 |
| CN100484536C true CN100484536C (en) | 2009-05-06 |
Family
ID=37296348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100185982A Expired - Fee Related CN100484536C (en) | 2006-03-16 | 2006-03-16 | Capsule for treating enteritis and dysentery and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100484536C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101912594A (en) * | 2010-08-11 | 2010-12-15 | 江西德瑞制药有限公司 | Traditional Chinese medicine preparation for treating gastrointestinal diseases |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102973629B (en) * | 2012-10-31 | 2014-10-22 | 河南牧翔动物药业有限公司 | Oral liquid for preventing and treating intestinal diseases of livestock and poultry and preparation method thereof |
-
2006
- 2006-03-16 CN CNB2006100185982A patent/CN100484536C/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| 部颁药品标准 中药成方制剂 第十三册. 中华人民共和国卫生部药典委员会,85. 1997 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101912594A (en) * | 2010-08-11 | 2010-12-15 | 江西德瑞制药有限公司 | Traditional Chinese medicine preparation for treating gastrointestinal diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1857360A (en) | 2006-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101569712B (en) | A kind of traditional Chinese medicine composition for treating cold and wind-cold | |
| CN104383250A (en) | A kind of Huajuhong cough dispersible tablet and preparation method thereof | |
| CN102085257A (en) | Preparation method of micro-pills prepared from cassia twig and tuckahoe | |
| CN104940781B (en) | It is a kind of to be used to treat Tibetan medicinal composition of white vein and preparation method thereof | |
| CN107890528B (en) | Traditional Chinese medicine composition for treating hyperuricemia and preparation method thereof | |
| CN100386103C (en) | Plaster for relieving asthma and stopping cough and its preparation method | |
| CN101461898B (en) | Chinese medicine solid preparation for treating climacteric syndrome and preparation method thereof | |
| CN100484536C (en) | Capsule for treating enteritis and dysentery and its preparing process | |
| CN102526665B (en) | Chinese medicinal particles for clearing heat, allaying fever and treating cold | |
| CN111419946A (en) | Medicine for treating infertility and preparation method thereof | |
| CN102274332B (en) | Process for preparing Chinese medicinal powder for treating peptic ulcer | |
| CN101317983A (en) | Method for preparing capsule for nourishing Yin and suppressing Yang, discharging fire and pacifying the mind | |
| CN100443113C (en) | Anshenbunao granule and preparation method thereof | |
| CN115531463A (en) | Traditional Chinese medicine for treating hyperlipidemia | |
| CN1686424B (en) | A pharmaceutical composition containing Scutellaria baicalensis and Bupleurum bupleuri and its preparation method | |
| CN101147767B (en) | Preparation method of medicinal composition for treating acne | |
| CN114533835B (en) | A Chinese medicinal composition with effects of removing pathogenic wind and dampness, and its preparation method | |
| JP7671874B2 (en) | Use of herbal medicine composition in the manufacture of a medicament for treating cough asthma | |
| CN103800449B (en) | A kind of Chinese medicine composition for the treatment of Yin Xu Nei Re Zheng type 2 diabetes mellitus | |
| JP2003135023A (en) | Health food | |
| CN101268794B (en) | Tea Bamboo Juice Complex and Its Application | |
| CN101317953A (en) | Method for preparing capsule for nourishing liquid, removing wind, nourishing Yin liquid | |
| CN101804143B (en) | Traditional Chinese medicine composition for treating urinary tract infection of perimenopausal women | |
| CN106309636B (en) | Pharmaceutical composition for uterine bleeding | |
| CN106177580B (en) | A kind of granule for treating type 2 diabetes and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090506 |